Letters to ALS: A New Book Unites the Canadian ALS Community

TORONTO, ON – March 26, 2026 – In a unique effort to foster connection and amplify the voices within the amyotrophic lateral sclerosis (ALS) community, Tanabe Pharma Canada, Inc. (TPC) has launched Letters to ALS: Our Journeys to Hope. The new book is a powerful collection of deeply personal letters written directly to the disease itself by those whose lives it has irrevocably changed.

Featuring contributions from people living with ALS, their families, caregivers, clinicians, researchers, and advocates, the book provides an unfiltered window into the emotional landscape of the disease. The “Dear ALS” format allows for the expression of raw, often unspoken feelings—from anger and grief to resilience and profound hope. This initiative moves beyond conventional support, creating a shared narrative that aims to unite and empower a community facing one of medicine's most formidable challenges.

The Healing Power of a Collective Voice

ALS, also known as Lou Gehrig's disease, is a relentless neurodegenerative condition that attacks nerve cells in the brain and spinal cord, leading to progressive paralysis. According to the ALS Society of Canada, an estimated 4,000 Canadians are currently living with the disease, and approximately 80 percent of those diagnosed will die within two to five years. Against this stark backdrop, finding sources of strength and solidarity is crucial.

Letters to ALS serves as a testament to that search for connection. By personifying the disease as the recipient of these letters, contributors were given a unique space to articulate their journey.

“In any rare disease community, every story shared helps bring people closer together,” said Claudine Cook, Executive Director of the ALS Society of Quebec. “What makes this book special is that it offers a different way to express what it truly feels like to be impacted by ALS. It captures emotions that are not always easy to voice. By sharing these reflections, the community not only deepens understanding of ALS, but also strengthens connection and unites us in hope. This book stands as a powerful testament to the resilience of those affected and a reminder that no one faces this journey alone.”

Beyond the Pill: A New Era of Patient Engagement

This project represents a significant step in the evolving role of pharmaceutical companies, marking a shift from being solely drug providers to becoming active partners in holistic patient and community support. For Tanabe Pharma Canada, this initiative builds on a long-standing commitment to the Canadian ALS community that began with the company's establishment in 2018.

TPC was responsible for bringing Radicava (edaravone) to Canada, first as an intravenous treatment in 2018—the first new therapy for ALS in the country in nearly two decades—and later as a more convenient oral formulation in 2022. The development of Letters to ALS, in collaboration with patient organizations across Canada, underscores a strategy that extends “beyond the pill” to address the profound emotional and psychological needs of patients and their families.

“Working alongside the ALS community on this book has been one of the most meaningful and fulfilling experiences of my career,” commented Sophy Olafson, a Neurology Account Specialist at TPC. She noted that the letters created a space for “raw emotions like anger, grief, compassion, resilience, and hope” to be freely expressed, offering insights that fuel hope for others.

While many corporate patient support programs focus on practicalities like insurance navigation or financial aid, this project delves into the narrative and emotional core of the patient experience, an innovative approach that fosters empathy and public awareness for a disease often misunderstood.

The Unseen Frontline of Clinicians and Researchers

The book also illuminates the perspectives of the healthcare professionals who dedicate their lives to fighting ALS. Letters from neurologists, researchers, nurses, and other specialists reveal the deep personal connections that drive their work far beyond the confines of the clinic.

“As clinicians, we most often interact with our patients in the context of delivering medical care—discussing symptoms, treatment options, and other clinical decisions. What is less visible are the passion we carry alongside that work,” explained Dr. Angela Genge, Neurologist and Director of the Clinical Research Unit at The Neuro (Montreal Neurological Institute-Hospital). “Caring for individuals affected by ALS is profoundly personal, and it shapes us in ways that extend far beyond the clinic. This personal connection is what drives our commitment to research that will ultimately help improve the lives of people living with ALS.”

This commitment is reflective of Canada's position as a global leader in ALS research. Bolstered by significant funding, including millions raised through the Ice Bucket Challenge and matched by Brain Canada, Canadian researchers are at the forefront of numerous clinical trials and studies. Initiatives like the Letters to ALS book complement this scientific push by humanizing the fight and reinforcing the urgency that researchers and clinicians feel every day.

Bridging Gaps in a Challenging Landscape

Despite progress in research and treatment, the Canadian ALS community continues to face significant systemic challenges. The journey to a diagnosis can take an average of 21 months, a critical delay for a rapidly progressing disease. Furthermore, patients and families often struggle to access adequate home care, specialized equipment, and other essential support services.

In this context, initiatives that raise public consciousness are invaluable. Letters to ALS: Our Journeys to Hope is available free of charge to all Canadians online through Google Play Books, ensuring wide accessibility. A limited run of printed copies will also be distributed through ALS clinics and patient advocacy groups, placing these powerful stories directly into the hands of the community.

By capturing the unfiltered reality of living with and fighting against ALS, the book serves not only as a source of comfort and solidarity for those directly affected but also as an educational tool for the public and policymakers. It highlights the immense courage of the ALS community and reinforces the collective call for improved care, faster access to therapies, and a continued, unwavering commitment to finding a cure.